Home Tags HuMax-TAC

Tag: HuMax-TAC

Preclinical Study Supports Continued Evaluation of CD25-targeted ADC in Selected Advanced...

Preclinical data for camidanlumab tesirine (formerly ADCT-301; ADC Therapeutics), published in the Journal for ImmunoTherapy of Cancer, the online journal of the Society for...

First Patient Dosed in Phase Ib Clinical Trial of Camidanlumab Tesirine...

A first patient has been dosed in Phase Ib clinical trial of camidanlumab tesirine, also know ADCT-301, a proprietary antibody-drug conjugate or ADC being...

ADC Therapeutics and Genmab Agree to Develop Antibody-drug Conjugate

Earlier this week Swiss-based oncology drug development company ADC Therapeutics Sarl and Danish Genmab A/S agreed to develop a new antibody-drug conjugate (ADC) combining HuMax®-TAC antibody...

X